James Treace - Dec 22, 2021 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for James T. Treace
Stock symbol
TMCI
Transactions as of
Dec 22, 2021
Transactions value $
-$706,242
Form type
4
Date filed
12/27/2021, 07:09 PM
Previous filing
Dec 22, 2021
Next filing
Dec 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale -$381K -23.4K -53.16% $16.28 20.6K Dec 22, 2021 By J&A Group LLC F1, F2, F3
transaction TMCI Common Stock Sale -$213K -12.6K -61.18% $16.90 8K Dec 23, 2021 By J&A Group LLC F1, F2, F4
transaction TMCI Common Stock Sale -$112K -6.44K -80.44% $17.46 1.57K Dec 27, 2021 By J&A Group LLC F1, F2, F5
holding TMCI Common Stock 1.01M Dec 22, 2021 By spouse
holding TMCI Common Stock 1.46M Dec 22, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.59 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.29 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.615 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.